Interleukin-6: A Masterplayer in the Cytokine Network von Uciechowski, Peter, Dempke, Wolfram C.M.

Volltext

Second- and third-generation drugs for immuno-oncology treatment—The more the better? von Dempke, Wolfram C.M, Fenchel, Klaus, Uciechowski, Peter, Dale, Stephen P

Volltext

Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment? von Dempke, Wolfram C.M., Uciechowski, Peter, Fenchel, Klaus, Chevassut, Timothy

Volltext

KEAP1/NRF2 (NFE2L2) mutations in NSCLC – Fuel for a superresistant phenotype? von Dempke, Wolfram C.M., Reck, Martin

Volltext

Anthracycline-induced cardiotoxicity — are we about to clear this hurdle? von Dempke, Wolfram C.M., Zielinski, Rafal, Winkler, Christina, Silberman, Sandra, Reuther, Susanne, Priebe, Waldemar

Volltext

Targeting the undruggable: menin inhibitors ante portas von Dempke, Wolfram C. M., Desole, Maximilian, Chiusolo, Patrizia, Sica, Simona, Schmidt-Hieber, Martin

Volltext

Targeted therapies for non-small cell lung cancer von Dempke, Wolfram C.M, Suto, Tamas, Reck, Martin

Volltext

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents von Dempke, Wolfram C.M, Heinemann, Volker

Volltext

Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? von Dempke, Wolfram C M, Edvardsen, Klaus, Lu, Shun, Reinmuth, Niels, Reck, Martin, Inoue, Akira

Volltext

Targeting Developmental Pathways: The Achilles Heel of Cancer? von Dempke, Wolfram C.M., Fenchel, Klaus, Uciechowski, Peter, Chevassut, Timothy

Volltext

Targeted Therapy for NSCLC--A Double-edged Sword? von Dempke, Wolfram C M

Volltext

Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-review von Dempke, Wolfram C M, Fenchel, Klaus

Volltext

Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review von Dempke, Wolfram C. M., Fenchel, Klaus

Volltext

TET2 cascade: a novel regulator of chromatin structure and leukaemogenesis von Dempke, Wolfram C. M., Fenchel, Klaus

Volltext

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis von Manz, Kirsi M., Fenchel, Klaus, Eilers, Andreas, Morgan, Jonathan, Wittling, Kirsten, Dempke, Wolfram C. M.

Volltext

Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree? von Dempke, Wolfram C. M., Fenchel, Klaus, Dale, Stephen P.

Volltext

Immunotherapies for NSCLC: Are We Cutting the Gordian Helix? von Dempke, Wolfram C M, Sellmann, Ludger, Fenchel, Klaus, Edvardsen, Klaus

Volltext

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer von Liang, Wenhua, Cai, Kaican, Chen, Chun, Chen, Haiquan, Chen, Qixun, Fu, Junke, Hu, Jian, Jiang, Tao, Jiao, Wenjie, Li, Shuben, Liu, Deruo, Liu, Wei, Liu, Yang, Ma, Haitao, Pan, Xiaojie, Qiao, Guibin, Tian, Hui, Wei, Li, Zhang, Yi, Zhao, Song, Zhao, Xiaojing, Zhou, Chengzhi, Zhu, Yuming, Zhong, Ran, Li, Feng, Rosell, Rafael, Provencio, Mariano, Massarelli, Erminia, Antonoff, Mara B., Hida, Toyoaki, de Perrot, Marc, Lin, Steven H., Di Maio, Massimo, Rossi, Antonio, de Ruysscher, Dirk, Ramirez, Robert A., Dempke, Wolfram C. M., Camidge, D. Ross, Guibert, Nicolas, Califano, Raffaele, Wang, Qi, Ren, Shengxiang, Zhou, Caicun, He, Jianxing

Volltext

Overall survival in non-small cell lung cancer—what is clinically meaningful? von Fenchel, Klaus, Sellmann, Ludger, Dempke, Wolfram C. M.

Volltext

Oncogene alterations in non-small cell lung cancer—have we MET a new target? von Dempke, Wolfram C. M., Reuther, Susanne, Hamid, Zohdy, Thoennissen, Nils H.

Volltext